IMP: Shining a spotlight on obesity treatment in NAFLD/NASH - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
IMP: Shining a spotlight on obesity treatment in NAFLD/NASH - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
IMP: Shining a spotlight on obesity treatment in NAFLD/NASH - ILC 2021
View
Metabolism, Alcohol & Toxicity
2
Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
Metabolism, Alcohol & Toxicity
2
Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
Metabolism, Alcohol & Toxicity
1
Bristol Myers Squibb: NASH: An evolution in treatment response tools - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021
View
Metabolism, Alcohol & Toxicity
3
Siemens: Non-Invasive Assessment of Liver Fibrosis in Chronic Liver Diseases - ILC 2021
